FindTrial
Sign In

Effect of yoga on lung and nerve functions in patients with rheumatoid arthritis

Effect of 12 weeks yoga therapy on pulmonary function and nerve conduction in patients with rheumatoid arthritis - A randomised control trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/09/036544
Enrollment
150
Registered
2021-09-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M058- Other rheumatoid arthritis with rheumatoid factor

Interventions

Intervention1: YOGA: If participants are in study group, they will be taught to perform yoga which includes asanas and pranayamas by a qualified yoga instructor in the ACYTER (JIPMER Yoga centre) for

Sponsors

Jawaharlal Institute of Postgraduate Medical Education and Research JIPMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Confirmed cases of RA in the age group of more than 18 years. 2)Disease activity score (DAS28ESR) more than 2.6

Exclusion criteria

Exclusion criteria: 1)Seronegative arthritis 2) Pregnant women 3)Other autoimmune conditions like SLE, psoriatic arthritis 4) Patients with deformity of limbs 5)Patients with extra articular manifestations

Design outcomes

Primary

MeasureTime frame
To study the pulmonary function and nerve function in patients with rheumatoid arthritis. To study the effect of 12 weeks yoga therapy on pulmonary function and nerve function in patients with rheumatoid arthritis. Improvement in pulmonary Function Test parameters like FEV1, FVC, FEV1/FVC, FEF 25%-75%, PEFR and nerve conduction parameters like distal latency, amplitude and nerve conduction velocity. Timepoint: baseline and at the end of 12 weeks.—

Secondary

MeasureTime frame
improvement in Biochemical and hematological parameters such as Hb, WBC, ESR, CRP, Anticcp, RF, IL-1, IL-6, IL-17, TNF-α, Malondialdehyde, total antioxidants and clinical signs such as swelling and tenderness in the joints.Timepoint: baseline and at the end of 12 weeks.—

Countries

India

Contacts

Public ContactHariprasad R

Jawaharlal institute of postgraduate medical education and research (JIPMER)

drpravatipal@gmail.com9360682406

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026